comparemela.com

Latest Breaking News On - Darren mcguire - Page 1 : comparemela.com

Wegovy weight-loss medication gets FDA approval for use as heart disease prevention drug

The injectable semaglutide from Novo Nordisk was shown to reduce risk of cardiovascular death, heart attack and stroke.

United statesJohn sharrettsBrooke boyarsky prattCarsten snejbjerg bloombergSteffen trumpfDarren mcguireNovo nordiskDivision of diabetesLipid disordersDrug evaluationGetty imagesDenmark based novo nordiskBoyarsky prattFox newsFox news digitalNews digital

Wegovy weight-loss medication gets FDA approval for use as heart disease prevention drug

The injectable semaglutide from Novo Nordisk was shown to reduce risk of cardiovascular death, heart attack and stroke.

United statesCarsten snejbjerg bloombergBrooke boyarsky prattJohn sharrettsSteffen trumpfDarren mcguireNovo nordiskDivision of diabetesLipid disordersDrug evaluationGetty imagesDenmark based novo nordiskBoyarsky prattFox newsFox news digitalNews digital

Wegovy, the weight-loss medication, gets FDA approval for use as heart disease prevention drug

Wegovy has been FDA-approved for heart disease prevention. The semaglutide, originally approved for weight loss, is now approved to reduce the risk of cardiovascular death, heart attack and stroke.

United statesDarren mcguireJohn sharrettsBrooke boyarsky prattDivision of diabetesNovo nordiskLipid disordersDrug evaluationDenmark based novo nordiskBoyarsky prattFox newsFox news digitalNews digital

Wegovy weight-loss medication gets FDA approval for use as heart disease prevention drug

The injectable semaglutide from Novo Nordisk was shown to reduce risk of cardiovascular death, heart attack and stroke.

United statesDarren mcguireJohn sharrettsSteffen trumpfCarsten snejbjerg bloombergBrooke boyarsky prattDivision of diabetesNovo nordiskLipid disordersDrug evaluationGetty imagesDenmark based novo nordiskBoyarsky prattFox newsFox news digitalNews digital

Wegovy weight-loss medication gets FDA approval for use as heart disease prevention drug

The injectable semaglutide from Novo Nordisk was shown to reduce risk of cardiovascular death, heart attack and stroke.

United statesCarsten snejbjerg bloombergBrooke boyarsky prattDarren mcguireSteffen trumpfJohn sharrettsNovo nordiskDivision of diabetesLipid disordersDrug evaluationGetty imagesDenmark based novo nordiskBoyarsky prattFox newsFox news digitalNews digital

vimarsana © 2020. All Rights Reserved.